App-Quantinova.ai

Making chemotherapy more patient friendly: a new approach to improve quality of care in ambulatory treatment.

A. Saxena - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Constipation

N/A

A Comparison of Hybridisation and Amplicon‐Based Methods for Next Generation Sequencing of Poor Quality Formalin‐Fixed Paraffin‐Embedded Lymphoma Tissue Samples

L. Miller - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

N/A

Successful treatment of primary cutaneous diffuse large B cell lymphoma leg type with single agent venetoclax

C.S. Trethewey - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Venetoclax

Responses to BTK inhibitors in mantle cell lymphoma post allogeneic stem cell transplant

S. Wharin - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Entospletinib

Single centre outcome of patients with secondary central nervous system lymphoma

J. Khwaja - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

CNS lymphoma

Methotrexate

Improving the Management of patients with HIV associated lymphoma in Greater Manchester

L. Carter-Brzezinski - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Hodgkin's Lymphoma

Rituximab

Secondary Central Nervous System Prophylaxis in Lymphoma Patients; the Bristol Experience

N. Chavda - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Diffuse large B-cell lymphoma

Methotrexate

Focal bone lesions in Hairy Cell Leukaemia

M. Cross - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hairy cell leukemia

N/A

Altering the balance of Rho GTPase pathways in CLL determines CLL cell fate

Y. Samir - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

AT-13148

Quality of 2 week referrals to Haematology Centres – An audit of night sweats

D. Mannari - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Essential thrombocythemia

N/A

Molecular remissions are observed in chronic adult T‐cell leukaemia/lymphoma in patients treated with mogamulizumab

L. Cook - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Adult T-Cell Leukemia

Mogamulizumab

Reducing bone marrow biopsy staging at diagnosis for diffuse large B‐cell lymphoma: results of a single‐centre audit before and after a locally‐produced guideline

S.C. Mackenzie - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Incidence and grade of non‐melanoma skin cancers in patients of long‐term Bruton's Tyrosine Kinase inhibitor therapy: a single centre study

J. Vaz - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Waldenstrom’s macroglobulinemia

ACP-196

In field relapses following involved site radiotherapy to limited stage or localised residual double hit high grade B cell lymphoma: a review of 4 consecutive cases at the Royal Marsden Hospital.

M. Cross - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

N/A

Single centre experience of compassionate use lenalidomide in haematological malignancies: a case series.

A. Martin - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Lenalidomide

A Quality Improvement Project Assessing Concordance with British Society for Haematology (BSH) Guidelines Regarding Management of Diffuse Large B‐Cell Lymphoma

P. Mahapatra - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Diffuse large B-cell lymphoma

Cyclophosphamide

Daratumumab in heavily pre‐treated patients: a single centre experience from the East of England.

D. Sparksman - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

daratumumab Intravenous

Is monitoring of Low Risk MGUS Low Risk? An audit of MGUS monitoring following discharge to primary care

L. Kamuriwo - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Monoclonal gammopathy

N/A

18F Fluorodeoxyglucose positron emission tomography‐CT (PET CT) scan as a diagnostic tool in newly diagnosed multiple myeloma (MM): Single centre experience in the United Kingdom (UK)

P. Player - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Urology

Multiple Myeloma

N/A

Clinical utility of bone marrow biopsy pre autograft in myeloma

A. Aggarwal - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Amyloid disease

N/A

Filters

45280 Abstracts